145 related articles for article (PubMed ID: 76325)
1. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
[No Abstract] [Full Text] [Related]
2. [Effect of hormonal therapy on plasma FSH, LH and testosterone levels in prostatic cancer].
Shirai M; Matsuda S; Mitsukawa S; Nakamura M; Yonezawa K
Nihon Hinyokika Gakkai Zasshi; 1975 Feb; 66(2):59-67. PubMed ID: 1168823
[No Abstract] [Full Text] [Related]
3. Hormonal status in prostatic disease.
Frick J; Bartsch G
Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
[No Abstract] [Full Text] [Related]
4. [Pre- and post-prostatectomy variation and supplement of sexual hormones in patients with benign prostatic hyperplasia].
Ren XM; Ying J; Yao DH; Jiang YQ; Xu MX
Zhonghua Nan Ke Xue; 2005 Jan; 11(1):50-2, 55. PubMed ID: 15704683
[TBL] [Abstract][Full Text] [Related]
5. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
6. [Determination of LH and FSH levels before and after prostatic adenomectomy (author's transl)].
Fontana D; Isaia GC; Fasolis G; Bertagna A; Borgno M; Molinatti GM
J Urol Nephrol (Paris); 1979; 85(7-8):479-84. PubMed ID: 93649
[TBL] [Abstract][Full Text] [Related]
7. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
Baranowska B; Zgliczynski S; Szymanowski J
J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
[TBL] [Abstract][Full Text] [Related]
8. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
Maleeva A; Tsvetkov M; Kekhaĭova M
Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
10. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
11. [Study of the interdependence between prostatic hypertrophy and disorders in hormone levels. Preliminary report. 1. Study of blood testosterone].
Szymanoski J; Baranowska B; Migdalska B; Kozlowicz I
J Urol Nephrol (Paris); 1976; 82(10-11):827-36. PubMed ID: 63569
[TBL] [Abstract][Full Text] [Related]
12. [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
Z Urol Nephrol; 1987 Dec; 80(12):665-8. PubMed ID: 3126615
[TBL] [Abstract][Full Text] [Related]
13. [Hormonal changes in carcinoma of the prostate].
Rodrigues-Netto Júnior N; Da Silva RP; Hernández AJ
Rev Paul Med; 1979; 94(1-2):24-6. PubMed ID: 120973
[No Abstract] [Full Text] [Related]
14. [The influence of spironolactone on the concentration of gonadotrophins and gonadal hormones in prostatic hypertrophy (author's transl)].
Zgliczynski S; Baranowska B; Szymanowski J
J Urol (Paris); 1981; 87(9):635-8. PubMed ID: 6174646
[TBL] [Abstract][Full Text] [Related]
15. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
16. A study of the endocrine manifestations of hepatic cirrhosis.
Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
[TBL] [Abstract][Full Text] [Related]
17. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
19. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
[No Abstract] [Full Text] [Related]
20. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
